Relapsing Remitting Multiple Sclerosis Drug Pipeline Analysis Report 2025

In the United States, around 1 million people are living with multiple sclerosis. Out of these, 80-85% of people diagnosed with multiple sclerosis have relapsing-remitting multiple sclerosis, making it the most common sub-type. Therefore, researchers are emphasizing on developing high-quality and potent drugs to manage the disease effectively.

Report Coverage

The Relapsing Remitting Multiple Sclerosis Drug Pipeline Insight Report by the publisher gives comprehensive insights into relapsing remitting multiple sclerosis drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for relapsing remitting multiple sclerosis. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The relapsing remitting multiple sclerosis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from relapsing remitting multiple sclerosis.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing relapsing remitting multiple sclerosis product development activities related to relapsing remitting multiple sclerosis.

Relapsing Remitting Multiple Sclerosis Drug Pipeline Outlook

Relapsing-remitting multiple sclerosis (RRMS) is a type of multiple sclerosis. Multiple sclerosis is an autoimmune disorder that affects the central nervous system. It causes the immune system to attack the insulation protection on the nerves called myelin, leading to difficulties in passing signals. With relapsing-remitting multiple sclerosis, an individual witnesses flare-ups or remissions. It is the most common type of multiple sclerosis. Most individuals diagnosed with the disease start with RRMS.

There are different treatment alternatives available to treat the diseases. These work by slowing down disease progression and reducing inflammation. The route of administration can be oral, or infusion based.

Relapsing Remitting Multiple Sclerosis - Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of relapsing remitting multiple sclerosis drug candidates based on several segmentations including:

By Phase

The pipeline assessment report covers 50+ drug analyses based on phase.

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

The relapsing remitting multiple sclerosis therapeutic assessment report covers 50+ drug analyses based on drug classes:

• Immunomodulators
• Oral Disease-Modifying Therapies
• Monoclonal Antibodies
• Selective Adhesion Molecule Inhibitors
• Immunosuppressants

By Route of Administration

The pipeline assessment report covers 50+ drug analyses based on the route of administration.

• Oral
• Parenteral
• Others

Relapsing Remitting Multiple Sclerosis - Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total clinical trials for relapsing remitting multiple sclerosis. There are around 142 drugs in phase II of relapsing remitting multiple sclerosis drugs.

Relapsing Remitting Multiple Sclerosis - Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under relapsing remitting multiple sclerosis pipeline analysis include immunomodulators, oral disease-modifying therapies, monoclonal antibodies, selective adhesion molecule inhibitors and immunosuppressants. The choice of treatment depends on the stage of the disease, patient allergies, and multiple factors.

Relapsing Remitting Multiple Sclerosis Clinical Trials Therapeutic Assessment - Competitive Dynamics

The report for the relapsing remitting multiple sclerosis drug insights covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in relapsing remitting multiple sclerosis clinical trials:

• Celgene
• Hoffmann-La Roche
• Hikma Pharmaceuticals LLC
• Biogen
• Merck KGaA
• Bristol-Myers Squibb
• GlaxoSmithKline
• Novartis Pharmaceuticals
• Bayer
• Eli Lilly and Company

Relapsing Remitting Multiple Sclerosis - Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for spinal fusion. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of spinal fusion drug candidates.

ANK-700

This drug is under investigation for its safety and tolerability against relapsing remitting multiple sclerosis in adults. Sponsored by Anokion SA, the Phase 1 study is divided into 2 arms, wherein the patients in part A receive a single dose of the drug while the patients in part B will either receive 3 doses of ANK-700 or placebo.

Ocrelizumab

Roche is conducting a Phase 3 randomised, double-blind, multicenter study to examine the efficacy and safety of the drug in comparison to finglomod taken orally. Ocrelizumab will be intravenously administered every 24 weeks to children as well as adolescents (aged between 10-18 years) affected with relapsing-remitting multiple sclerosis.

IMCY-0141

Sponsored by Imcyse SA, this experimental drug is in Phase 1 for treating relapsing-remitting multiple sclerosis. Based on a new mechanism, it is part of an interventional study that has 150 participants.

Reasons To Buy This Report

The Relapsing Remitting Multiple Sclerosis Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for relapsing remitting multiple sclerosis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into relapsing remitting multiple sclerosis collaborations, regulatory environments, and potential growth opportunities within relapsing remitting multiple sclerosis pipeline insights.

Key Questions Answered in the Relapsing Remitting Multiple Sclerosis - Pipeline Insight Report

• Which companies/institutions are leading the relapsing remitting multiple sclerosis development?
• What is the efficacy and safety profile of spinal fusion pipeline drugs?
• Which company is leading the relapsing remitting multiple sclerosis pipeline development activities?
• What is the current relapsing remitting multiple sclerosis commercial assessment?
• What are the opportunities and challenges present in the relapsing remitting multiple sclerosis drug pipeline landscape?
• What is the efficacy and safety profile of relapsing remitting multiple sclerosis pipeline drugs?
• Which company is conducting major trials for relapsing remitting multiple sclerosis drugs?
• Which companies/institutions are involved in relapsing remitting multiple sclerosis collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in spinal fusion?

This product will be delivered within 3-5 business days.